Susan C Charman
Overview
Explore the profile of Susan C Charman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
856
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Semenchuk J, Naito Y, Charman S, Carr S, Cheng S, Marshall B, et al.
J Cyst Fibros
. 2024 Aug;
23(5):815-822.
PMID: 39191560
Background: Factors associated with severe COVID-19 infection have been identified; however, the impact of infection on longer-term outcomes is unclear. The objective of this study was to examine the impact...
2.
Stanford G, Jones M, Charman S, Bilton D, Usmani O, Davies J, et al.
Ther Adv Respir Dis
. 2022 Sep;
16:17534666221122572.
PMID: 36066081
Background: Airway clearance techniques (ACTs) are integral to cystic fibrosis (CF) management. However, there is no consensus as to which outcome measures (OMs) are best for assessing ACT efficacy. Objectives:...
3.
Desai M, Hine C, Whitehouse J, Brownlee K, Charman S, Nagakumar P
Respir Med
. 2022 May;
199:106878.
PMID: 35633605
Background: The availability of mutation-specific cystic fibrosis modulator therapies has the potential to improve the lives of children and adults with cystic fibrosis. The frequency of mutations causing defects in...
4.
Schluter D, Ostrenga J, Carr S, Fink A, Faro A, Szczesniak R, et al.
Thorax
. 2021 May;
77(2):136-142.
PMID: 33975926
Rationale: A previous analysis found significantly higher lung function in the US paediatric cystic fibrosis (CF) population compared with the UK with this difference apparently decreasing in adolescence and adulthood....
5.
Kaplan S, Lee A, Caine N, Charman S, Bilton D
J Cyst Fibros
. 2020 Aug;
20(2):324-329.
PMID: 32807645
Background: As part of the risk management plan in Europe, a long-term observational study was conducted to monitor the safety of colistimethate sodium dry powder for inhalation (CMS-DPI) compared to...
6.
Nossiter J, Sujenthiran A, Cowling T, Parry M, Charman S, Cathcart P, et al.
J Clin Oncol
. 2020 Jan;
38(7):744-752.
PMID: 31895608
Purpose: The aim of the current study was to determine patient-reported functional outcomes in men with prostate cancer (PCa) undergoing moderately hypofractionated (H-RT) or conventionally fractionated radiation therapy (C-RT) in...
7.
Eldred-Evans D, Neves J, Simmons L, Kanthabalan A, McCartan N, Shah T, et al.
BJU Int
. 2019 Nov;
125(3):391-398.
PMID: 31733173
Objective: To determine the additional diagnostic value of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced imaging (DCE) in men requiring a repeat biopsy within the PICTURE study. Patients And Methods: PICTURE...
8.
Frost F, Nazareth D, Charman S, Winstanley C, Walshaw M
Ann Am Thorac Soc
. 2019 Jul;
16(11):1375-1382.
PMID: 31319678
Ivacaftor can greatly improve clinical outcomes in people with cystic fibrosis (CF) and has been shown to have antibacterial properties, yet the long-term microbiological outcomes of treatment are unknown. To...
9.
Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, et al.
J Cyst Fibros
. 2019 Jun;
19(1):68-79.
PMID: 31196670
Background: Ivacaftor is the first in a class of drugs, CFTR modulators, that target the underlying defect in cystic fibrosis (CF). This long-term observational safety study evaluated CF disease progression...
10.
Simmons L, Kanthabalan A, Arya M, Briggs T, Charman S, Freeman A, et al.
Prostate Cancer Prostatic Dis
. 2018 Oct;
22(2):261-267.
PMID: 30279583
Background: Men with negative prostate biopsies or those diagnosed with low-risk or low-volume intermediate-risk prostate cancers often require a second prostate biopsy prior to a treatment decision. Prostate HistoScanning (PHS)...